The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | Ruxolitinib in 2022: how this agent has transformed the MF treatment landscape
In this video, Aaron Gerds, MD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the role of ruxolitinib in the treatment of myeloproliferative neoplasms (MPNs), drawing focus on how this agent has transformed the treatment landscape of myelofibrosis (MF). Dr Gerds first provides some background information on the development and approval of ruxolitinib, and then goes on to explain how this agent has greatly improved patient outcomes over the years. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Consulting/Advisory for CTI Biopharma, GSK/Sierra Oncology, Morphosys, ParmaEssentia, Imago, AbbVie
